2010 to be an active year for new drug applications.
Kees Leenhouts, MucosisThe general global pharmaceutical sector experienced a positive sales trend throughout 2009 as the unwanted effects of the global recession eased provided the economic recovery in various countries. Most of the large pharmaceutical companies mentioned in the report experienced their most challenging product sales period in the 1st quarter of 2009 and noticed regular improvement thereafter. Fitch anticipates that this positive operational momentum will bring in to the first one fourth of 2010 in light of the less than optimal performance in the same period this past year. For complete late-stage R&D pipeline advancements, recent commercialization, and an in-depth fourth-quarter review of the global pharmaceutical sector, start to see the special report, ‘Global Pharmaceutical R&D Pipeline – Fourth Quarter 2009’ available these days at ‘ SOURCE Fitch Ratings..We anticipate helping you full your projects on sending a costs to President Obama that developments these essential shared goals. .. Thomas J. Louie, M.D., Mark A. Miller, M.D., Kathleen M. Mullane, D.O., Karl Weiss, M.D., Arnold Lentnek, M.D., Yoav Golan, M.D., Sherwood Gorbach, M.D., Pamela Sears, Ph.D., and Youe-Kong Shue, Ph.D. For the OPT-80-003 Clinical Study Group: Fidaxomicin versus Vancomycin for Clostridium difficile Infection Clostridium difficile infection generally occurs after exposure to broad-spectrum antibiotics.